Daiichi Sankyo unit accuses Pharmacosmos of patent infringement

American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Seagen targets Daiichi in cancer drug suit

22 October 2020 US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.

Big Pharma

Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute

14 November 2019 Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.

Big Pharma

AstraZeneca and Daiichi Sankyo to develop new cancer treatment

2 April 2019 Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.

More features

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

Why AI is changing the patent rules faster than anyone can keep up

The hidden code in life sciences deals

LSPN panel unpacks critical IP risks in deal-making

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

Daiichi Sankyo unit accuses Pharmacosmos of patent infringement

More on this story

Editor's picks

Editor's picks

More features